The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+, HER2- advanced breast cancer.
Bent Ejlertsen
Research Funding - Amgen; Novartis
Other Remuneration - Novartis
Guy Heinrich Maria Jerusalem
Consultant or Advisory Role - Novartis
Sara A. Hurvitz
Research Funding - Novartis; Roche
Other Remuneration - Novartis; Roche
Richard H. De Boer
Consultant or Advisory Role - Novartis; Roche
Tanya Taran
Employment or Leadership Position - Novartis
Tarek Sahmoud
Employment or Leadership Position - Novartis
Howard A. Burris
No relevant relationships to disclose